Connect your AI

Bruker BRKR Bsi Biospin — Restructuring And Related Cost Incurred Cost

Other segment segments

Bsi Calid

$2M—

Corporate

$300K—

Bsi Nano

-$100K—

Similar metrics at other companies

PFEBiopharma — Restructuring cost incurred to date

$3.3B+22.2%

IFFHealth & Biosciences — Restructuring Charges

$2M-33.3%

RVTYLife Sciences — Restructuring and Other Costs (Income)

$3.23M+27.7%

TMOLife Sciences Solutions — Restructuring and other costs

$9M—

TMOLaboratory Products and Biopharma Services — Restructuring and other costs

$33M—

ARWCorporate — Restructuring And Related Cost Incurred Cost

$36.7M+112%

Other financials

Income statement

Revenue$823.4M+2.7%

Gross profit$379.8M-2.9%

Operating income$10.2M-67.9%

Net income$14.4M-17.2%

EPS (diluted)$0.02-81.8%

Balance sheet

Cash & equivalents$137.6M-26.7%

Total debt$1.7B-20.9%

Total equity$2.5B+34.6%

Total assets$6.1B+3.3%

Cash flow

Operating cash flow$71.2M+9.5%

CapEx$24.2M-6.9%

Free cash flow$47.0M+20.5%

Valuation

Market cap$8.71B-13.2%

Enterprise value$10.25B-14.9%

P/S2.5×-0.4×

Profitability

Gross margin45.3%-3.7pp

Operating margin1.3%-5.0pp

Net margin-0.6%-10.0pp

FCF margin1.5%-3.6pp

Returns & leverage

Return on equity-1%-21.2pp

Debt / equity0.7×-0.5×

Current ratio1.6×0.0×

Where this comes from

Reported directly by Bruker in its filing.

Tagged under the XBRL concept us-gaap:RestructuringAndRelatedCostIncurredCost.

The official record: Bruker’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bruker's bsi biospin — restructuring and related cost incurred cost.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bruker's bsi biospin — restructuring and related cost incurred cost?: Bruker (BRKR) reported bsi biospin — restructuring and related cost incurred cost of $3M in Q1 2026.
What does bsi biospin — restructuring and related cost incurred cost mean?: This represents the actual cash or accrual costs incurred by the BioSpin segment specifically tied to the execution of restructuring initiatives. It provides transparency into the financial impact of strategic shifts beyond the initial charge. Tracking this helps investors understand the total cost of organizational transformation.